Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol

Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol

Abstract Background Mixed dyslipidemia [elevated non-high-density lipoprotein cholesterol (non-HDL-C) and triglycerides (TGs), and decreased HDL-C] is common in type 2 diabetes mellitus (T2DM) and is associated with increased cardiovascular risk. Non-HDL-C and apolipoprotein B (ApoB) are the preferr...

Full description

Bibliographic Details
Main Authors: Helen M. Colhoun, Lawrence A. Leiter, Dirk Müller-Wieland, Bertrand Cariou, Kausik K. Ray, Francisco J. Tinahones, Catherine Domenger, Alexia Letierce, Marc Israel, Rita Samuel, Stefano Del Prato
Format: Article
Language:English
Published: BMC 2020-02-01
Series:Cardiovascular Diabetology
Subjects:
Alirocumab
PCSK9
Diabetes mellitus
Non-HDL-C
HDL-C
Triglycerides
Online Access:https://doi.org/10.1186/s12933-020-0991-1

Internet

https://doi.org/10.1186/s12933-020-0991-1

Similar Items